{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:47:43Z","timestamp":1770886063126,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10072-024-07769-1","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:09:04Z","timestamp":1726751344000},"page":"5813-5821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2665-231X","authenticated-orcid":false,"given":"Simone","family":"Migliore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Marcosano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"7769_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/B978-0-12-823357-3.00014-8","volume":"199","author":"C Altamura","year":"2024","unstructured":"Altamura C, Coppola G, Vernieri F (2024) The evolving concept of multimorbidity and migraine. Handb Clin Neurol 199:535\u2013566","journal-title":"Handb Clin Neurol"},{"key":"7769_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen MT, De Dhaem OB, Van Diest AK, Powers S, Schwedt TJ, Lipton R, Silbersweig D (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87:741\u2013749","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7769_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231180564","author":"N Pelzer","year":"2023","unstructured":"Pelzer N, de Boer I, van den Maagdenberg AMJM, Terwindt GM (2023) Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024231180564","journal-title":"Cephalalgia"},{"key":"7769_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1468-2982.2004.00839.x","volume":"25","author":"F Radat","year":"2005","unstructured":"Radat F, Swendsen J (2005) Psychiatric comorbidity in migraine: a review. Cephalalgia 25:165\u2013178","journal-title":"Cephalalgia"},{"key":"7769_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2023.1254290","author":"XM Androulakis","year":"2023","unstructured":"Androulakis XM, Yu X, Zhu X, Thiam MA, Cai G (2023) Migraine and major depression: localizing shared genetic susceptibility in different cell types of the nervous systems. Front Neurol. https:\/\/doi.org\/10.3389\/FNEUR.2023.1254290","journal-title":"Front Neurol"},{"key":"7769_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(24)00026-7","volume":"23","author":"HG Sutherland","year":"2024","unstructured":"Sutherland HG, Jenkins B, Griffiths LR (2024) Genetics of migraine: complexity, implications, and potential clinical applications. Lancet Neurol 23:429\u2013446","journal-title":"Lancet Neurol"},{"key":"7769_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1212\/01.WNL.0000058907.41080.54","volume":"60","author":"N Breslau","year":"2003","unstructured":"Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KMA (2003) Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 60:1308\u20131312","journal-title":"Neurology"},{"key":"7769_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/S41572-022-00415-0","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, Schwedt TJ, Jensen RH, Diener HC, Lipton RB (2023) Medication overuse headache. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/S41572-022-00415-0","journal-title":"Nat Rev Dis Primers"},{"key":"7769_CR9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1526-4610.2009.01457.x","volume":"49","author":"LM Cupini","year":"2009","unstructured":"Cupini LM, De MM, Costa C, Mancini M, Eusebi P, Sarchielli P, Calabresi P (2009) Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache 49:1005\u20131013","journal-title":"Headache"},{"key":"7769_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-016-0649-2","author":"C Lampl","year":"2016","unstructured":"Lampl C, Thomas H, Tassorelli C et al (2016) Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-016-0649-2","journal-title":"J Headache Pain"},{"key":"7769_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/FNHUM.2020.571035","author":"S Migliore","year":"2020","unstructured":"Migliore S, Paolucci M, Quintiliani L, Altamura C, Maffi S, D\u2019Aurizio G, Curcio G, Vernieri F (2020) Psychopathological Comorbidities and Clinical Variables in Patients With Medication Overuse Headache. Front Hum Neurosci. https:\/\/doi.org\/10.3389\/FNHUM.2020.571035","journal-title":"Front Hum Neurosci"},{"key":"7769_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 55:3\u201320","journal-title":"Headache"},{"key":"7769_CR13","doi-asserted-by":"publisher","unstructured":"Serrano D, Lipton RB, Scher AI, Reed ML, Stewart W (Buzz) F, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain https:\/\/doi.org\/10.1186\/S10194-017-0787-1","DOI":"10.1186\/S10194-017-0787-1"},{"key":"7769_CR14","first-page":"973","volume":"21","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD (2015) Preventive Migraine Treatment. Continuum (Minneap Minn) 21:973\u2013989","journal-title":"Continuum (Minneap Minn)"},{"key":"7769_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/TOXINS15040284","author":"C Altamura","year":"2023","unstructured":"Altamura C, Brunelli N, Viticchi G, Salvemini S, Cecchi G, Marcosano M, Fofi L, Silvestrini M, Vernieri F (2023) Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study. Toxins (Basel). https:\/\/doi.org\/10.3390\/TOXINS15040284","journal-title":"Toxins (Basel)"},{"key":"7769_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF (2020) Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache 60:1259\u20131272","journal-title":"Headache"},{"key":"7769_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024231152169","journal-title":"Cephalalgia"},{"key":"7769_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/S11916-023-01183-6","author":"C S\u00e1nchez-Rodr\u00edguez","year":"2023","unstructured":"S\u00e1nchez-Rodr\u00edguez C, Gago-Veiga AB, Garc\u00eda-Azor\u00edn D, Guerrero-Peral \u00c1L, Gonzalez-Martinez A (2023) Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data. Curr Pain Headache Rep. https:\/\/doi.org\/10.1007\/S11916-023-01183-6","journal-title":"Curr Pain Headache Rep"},{"key":"7769_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10072-020-04661-6","volume":"41","author":"C Altamura","year":"2020","unstructured":"Altamura C, Costa C, Fofi L et al (2020) Migraineurs\u2019 psychological traits do not influence response to erenumab. Neurol Sci 41:467\u2013468","journal-title":"Neurol Sci"},{"key":"7769_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-022-01498-6","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-022-01498-6","journal-title":"J Headache Pain"},{"key":"7769_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-021-01333-4","author":"B Sara","year":"2021","unstructured":"Sara B, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, Ghiotto N, Martinelli D, Tassorelli C, Sances G (2021) Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-021-01333-4","journal-title":"J Headache Pain"},{"key":"7769_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A (2021) Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 144:325\u2013333","journal-title":"Acta Neurol Scand"},{"key":"7769_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/BRAINSCI12111563","author":"G Viticchi","year":"2022","unstructured":"Viticchi G, Falsetti L, Salvemini S, Bartolini M, Paolucci S, Buratti L, Silvestrini M (2022) Efficacy of Onabotulinum Toxin A on Obsessive-Compulsive Traits in a Population of Chronic Migraine Patients. Brain Sci. https:\/\/doi.org\/10.3390\/BRAINSCI12111563","journal-title":"Brain Sci"},{"key":"7769_CR24","doi-asserted-by":"crossref","unstructured":"Olesen J (2018) Headache classification committee of the International Headache Society (IHS) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"7769_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-018-0955-Y","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-018-0955-Y","journal-title":"J Headache Pain"},{"key":"7769_CR26","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.13617","volume":"59","author":"F Vernieri","year":"2019","unstructured":"Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, Cevoli S, D\u2019Amico D, Grazzi L (2019) BoNT-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience. Headache 59:1300\u20131309","journal-title":"Headache"},{"key":"7769_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, Degryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793\u2013803","journal-title":"Cephalalgia"},{"key":"7769_CR28","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Ball R, Ranieri WF (1996) Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 67:588\u2013597","journal-title":"J Pers Assess"},{"key":"7769_CR29","unstructured":"Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists Press"},{"key":"7769_CR30","first-page":"141","volume":"16","author":"C Sighinolfi","year":"2010","unstructured":"Sighinolfi C, Pala AN, Chiri LR, Marchetti I, Sica C (2010) Difficulties in emotion regulation scale (DERS): traduzione e adattamento italiano. Psicoterapia Cogn Comport 16:141\u2013170","journal-title":"Psicoterapia Cogn Comport"},{"key":"7769_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jclp.1051","volume":"57","author":"A Fossati","year":"2001","unstructured":"Fossati A, Di Ceglie A, Acquarini E, Barratt ES (2001) Psychometric properties of an Italian version of the Barratt Impulsiveness Scale-11 (BIS-11) in nonclinical subjects. J Clin Psychol 57:815\u2013828","journal-title":"J Clin Psychol"},{"key":"7769_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0022-3999(96)00228-0","volume":"41","author":"C Bressi","year":"1996","unstructured":"Bressi C, Taylor G, Parker J et al (1996) Cross validation of the factor structure of the 20-item Toronto Alexithymia Scale: An Italian multicenter study. J Psychosom Res 41:551\u2013559","journal-title":"J Psychosom Res"},{"key":"7769_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2021.671845","author":"YY Chen","year":"2021","unstructured":"Chen YY, Ye XQ, Tang TC, She TW, Chen M, Zheng H (2021) Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis. Front Pharmacol. https:\/\/doi.org\/10.3389\/FPHAR.2021.671845","journal-title":"Front Pharmacol"},{"key":"7769_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-024-01721-6","author":"L Grazzi","year":"2024","unstructured":"Grazzi L, Giossi R, Montisano DA, Canella M, Marcosano M, Altamura C, Vernieri F (2024) Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-024-01721-6","journal-title":"J Headache Pain"},{"key":"7769_CR35","doi-asserted-by":"publisher","unstructured":"Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U (2023) Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-023-01552-X","DOI":"10.1186\/S10194-023-01552-X"},{"key":"7769_CR36","doi-asserted-by":"publisher","first-page":"E33874","DOI":"10.1097\/MD.0000000000033874","volume":"102","author":"C Rhyne","year":"2023","unstructured":"Rhyne C, Cohen JM, Seminerio MJ, Carr K, Krasenbaum LJ (2023) Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review. Medicine 102:E33874","journal-title":"Medicine"},{"key":"7769_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-022-01436-6","author":"M Silvestro","year":"2022","unstructured":"Silvestro M, Tessitore A, Orologio I, De Micco R, Tartaglione L, Trojsi F, Tedeschi G, Russo A (2022) Galcanezumab effect on \u201cwhole pain burden\u201d and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-022-01436-6","journal-title":"J Headache Pain"},{"key":"7769_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-021-02801-W","author":"O Affatato","year":"2021","unstructured":"Affatato O, Moulin TC, Pisanu C et al (2021) High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. J Transl Med. https:\/\/doi.org\/10.1186\/S12967-021-02801-W","journal-title":"J Transl Med"},{"key":"7769_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/TOXINS14060383","author":"MA Wollmer","year":"2022","unstructured":"Wollmer MA, Magid M, Kruger THC, Finzi E (2022) Treatment of Depression with Botulinum Toxin. Toxins (Basel). https:\/\/doi.org\/10.3390\/TOXINS14060383","journal-title":"Toxins (Basel)"},{"key":"7769_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-022-01471-3","author":"C Rosignoli","year":"2022","unstructured":"Rosignoli C, Ornello R, Onofri A, Caponnetto V, Grazzi L, Raggi A, Leonardi M, Sacco S (2022) Applying a biopsychosocial model to migraine: rationale and clinical implications. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-022-01471-3","journal-title":"J Headache Pain"},{"key":"7769_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-021-01335-2","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-021-01335-2","journal-title":"J Headache Pain"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07769-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07769-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07769-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T10:11:15Z","timestamp":1731319875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07769-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7769"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07769-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Claudia Altamura received travel grants and honoraria from Novartis, Eli Lilly, Allergan, Lusofarmaco, and Laborest, she serves as Associate Editor for Frontiers in Human Neuroscience. Fabrizio Vernieri received travel grants, honoraria for advisory boards, and speaker panels from Allergan, Angelini, Lilly, Lundbeck, Novartis, and Teva. Simone Migliore, Nicoletta Brunelli, Marilena Marcosano and Giuseppe Curcio have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All patients provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}